Diabetes and Your Eyes: How to Protect Your Vision
"Groundbreaking research highlights a new way to prevent vision loss from diabetic retinopathy"
Diabetic retinopathy (DR) is a major concern as one of the leading causes of vision loss among adults. While treatments like anti-VEGF injections and laser photocoagulation exist, they often have limited effectiveness or unwanted side effects. This creates a pressing need for more reliable and sustained approaches to safeguard vision for individuals with diabetes.
New research offers a beacon of hope for those at risk. The study, published in Investigative Ophthalmology & Visual Science, explores the potential of targeting a specific enzyme, lysyl oxidase (LOX), to prevent the development and progression of DR. The findings suggest that by inhibiting the overproduction of LOX, it may be possible to prevent the vascular damage associated with this debilitating condition.
This article breaks down the key findings of this study, explaining what LOX is, how it contributes to DR, and how this new research could pave the way for innovative treatments to protect your eyesight.
Screening and Treatment Standards
Diabetic retinopathy is a microvascular complication of diabetes mellitus and a leading cause of vision loss and blindness worldwide, particularly among people aged 20–74. More than 100 million people with diabetes experience the condition globally. The American Academy of Ophthalmology identifies a dilated fundus examination as the gold standard for screening, although validated digital imaging may also be effective; however, only 60% of people with diabetes receive recommended yearly screening. Panretinal laser photocoagulation is indicated to reduce vision-loss risk in people with high-risk proliferative diabetic retinopathy and, in some cases, severe nonproliferative disease.
Tracing Diabetic Retinopathy
Diabetic retinopathy has long been recognized as a diabetes complication related to disease duration, with classifications developed to organize diverse ophthalmoscopic findings and variable clinical courses. It is also described as the most common diabetes-associated microvascular complication and a leading cause of adult vision loss or blindness. Historical accounts note that after the discovery and use of insulin, the occurrence of diabetic retinopathy appeared to increase. In 1890, Julius Hirschberg classified diabetic retinopathy into four types: retinitis centralis punctuate, haemorrhagic form, retinal infarction, and haemorrhagic glaucoma.
Understanding Lysyl Oxidase (LOX) and Its Role in Diabetic Retinopathy
Lysyl oxidase (LOX) is an enzyme that plays a crucial role in the creation and maintenance of the structure around blood vessels. It helps to cross-link collagen and elastin, two essential proteins that give strength and flexibility to these structures. Think of it as the glue that holds the framework of your blood vessels together.
- Acellular capillaries (AC): These are capillaries that have lost their cells, becoming non-functional.
- Pericyte loss (PL): Pericytes are cells that support and stabilize capillaries. Their loss weakens the vessel walls.
New Directions in Research
Current reviews emphasize that diabetic retinopathy classification is crucial for assessing disease severity and preventing vision loss. Classification relies on retinal abnormalities detected during ocular examinations. Recent research also describes diabetic retinopathy as a major ocular complication and leading cause of blindness and visual impairment, especially among working-age adults, while warning that its global prevalence is expected to increase, particularly in low- and middle-income countries. A 2026 review highlights advances in imaging and treatment, along with technological developments intended to improve outcomes.
Why Early Detection Matters
Diabetic retinopathy may produce no symptoms at first, so relying on noticeable vision changes can fail to identify the disease early. The National Eye Institute reports that finding retinopathy early can help people take steps to protect their vision. WebMD describes diabetic retinopathy as a common complication of diabetes that affects vision. The Mayo Clinic notes that diabetic retinopathy, macular edema, glaucoma, or combinations of these conditions can lead to complete vision loss, especially when health problems are poorly managed.
Different Screening Priorities
The NIDDK reports that about one in three people with diabetes who are older than age 40 already have signs of diabetic retinopathy, which it identifies as the most common cause of vision loss in people with diabetes. Screening timing also varies by diabetes type and circumstances: the CDC advises an eye exam immediately when type 2 diabetes is diagnosed. The National Eye Institute describes a test that shows average blood sugar over the previous three months, providing a different type of information from an eye examination. Together, these sources distinguish retinal screening from blood-sugar assessment while emphasizing the need for timely evaluation.
The Future of Diabetic Retinopathy Treatment
This groundbreaking research offers hope for a future where vision loss from diabetic retinopathy is preventable. By understanding the role of LOX and developing targeted treatments like LOX siRNA, scientists are paving the way for more effective and sustained ways to protect the eyesight of individuals living with diabetes. While further research is needed, these findings mark a significant step forward in the fight against diabetic retinopathy and its devastating consequences.
Expanding the Research Frontier
As the number of people with diabetes rises worldwide, prevention, diagnosis, and treatment of diabetic retinopathy have become priorities for the medical and public-health communities. A 2024 American Academy of Ophthalmology report says significant advances have been made in preserving sight and treating vision loss over recent decades. However, gaps in care and the growing global diabetes epidemic make improving existing screening and treatments imperative. The continuing challenge is to extend these advances to the expanding population at risk.
A Growing Global Burden
Diabetic retinopathy is a leading cause of vision loss among middle-aged and older people globally, and early detection with prompt treatment can help prevent diabetes-related visual impairment. A 2024 review reports that the sharp rise in diabetes prevalence, especially type 2 diabetes, has made macular retinal disease a major cause of significant vision loss among children, working adults, and older people. That review also reports that diabetic retinopathy affects more than 103 million people worldwide. Recent research continues to examine changing global, regional, and national burdens of blindness and vision loss attributed to diabetic retinopathy.